Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline
Executive Summary
Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
You may also be interested in...
Roche And Illumina Sign 15-Year Partnership To Advance NGS Testing
Roche and Illumina have entered a 15-year, non-exclusive partnership to expand access to next-generation sequencing- based testing in cancer care.
Roche/Genentech Partnering Team: One Face For The World To See
Thomas Zioncheck, global head of neuroscience, ophthalmology and rare diseases, Roche Pharma Partnering, talks to In Vivo about Roche and Genentech’s united partnering group, 2019 successes, and highlights ahead for the big pharma’s neuroscience pipeline.
Sarepta Secures $1.15bn From Roche In Ex-US DMD Gene Therapy Deal
Including upfront payments, half of development costs for SRP-9001, $1.7bn in milestone fees and royalties on sales outside the US, Sarepta pegs deal’s value at $10bn-plus.
Need a specific report? 1000+ reports available
Buy Reports